Skip to main content

Table 1 Overview of the evaluated parameters

From: Frequently assessed and used prognostic factors for outcome after macular hole surgery: which is better?

  Overall Macular holes closed Macular holes open  
  n   n   n p
  189 86.7% 164 13.2% 25
Age (years) 67 (63; 72)
min. 43, max. 91
67 (62; 72)
min. 49, max. 91
70 (63; 79)
min. 43, max. 88
0.033#
Female 71.4% 135 70.7% 116 76.0% 19 0.812§
Axial length (mm) 23.23 (22.52; 23.64)
min. 23.44, max. 31.71)
23.44 (22.95; 24.37)
min. 20.97, max. 31.71)
23.23 (22.52; 23.64)
min. 20.9, max. 28.12)
0.061#
Pseudophakia 27.5% 52 25.6% 42 40.0% 10 0.153§
Duration of symptoms (days) 49 (21; 150)
min. 1, max. 720
42 (21; 120)
min. 1, max. 720
105 (21; 270)
min. 14, max. 720
0.097#
VA preop (logMAR) 0.7 (0.5; 1.0)
min. 0.1, max. 1.5
0.7 (0.5; 1.0)
min. 0.1, max. 1.5
1.0 (0.8; 1.0)
min. 0.4, max. 1.5
0.0002#
MLD (μm) 299 (209; 414.5)
min. 19, max. 1.067
281.5 (198; 371)
min. 19, max. 914
559 (444; 633)
min. 342, max. 1.067
< 0.0001#
BD (μm) 793 (537.5; 1046)
min. 163, max. 2147
752 (522; 958)
min. 163, max. 1674
1219 (1028; 1668)
min. 622, max. 2.147
< 0.0001#
H (μm) 432 (374; 492)
min. 203, max. 819
422.5 (365; 477)
min. 203, max. 819
506 (462; 594)
min. 336, max. 763
< 0.0001#
MHI 0.56 (0.44; 0.75)
min. 0.24, max. 1.72
0.61 (0.48; 0.76)
min. 0.24, max. 1.72
0.39 (0.35; 0.49)
min. 0.25, max. 0.67
< 0.0001#
DHI 0.41 (0.31; 0.50)
min. 0.03, max. 0.92
0.39 (0.30; 0.50)
min. 0.03, max. 0.92
0.43 (0.37; 0.55)
min. 0.21, max. 0.72
0.185#
THI 1.43 (1.10; 1.97)
min. 0.47, max. 19.27
1.55 (1.20; 2.05)
min. 0.47, max. 19.27
0.90 (0.74; 1.17)
min. 0.58, max. 1.65
< 0.0001#
Ar (mm2) 0.09 (0.06; 0.18)
min. 0.01, max. 1.26
0.08 (0.05; 0.15)
min. 0.01, max. 1.26
0.27 (0.19; 0.36)
min. 0.09, max. 0.96
< 0.0001#
Cy (pixels) 6897 (2977; 10,643)
min. 0, max. 31,383
6122.5 (2667; 10,228)
min. 0, max. 25,375
10,851 (8057; 19,008)
min. 3388, max. 31,383
< 0.0001#
Vitreomacular traction 24.8% 47 27.4% 45 8.0% 2 0.036§
Epiretinal membrane 24.8% 47 23.9% 39 32.0% 8 0.315§
Surgeon A/B/C A: 28.0%/B: 38.6%/C: 33.3% A: 53/B: 73/C:63 83.0%/84.9%/92.1% A: 44/B: 62/C: 58 A: 17%/B: 15.1%/C: 7.9% A: 9/B: 11/C: 5 0.301$
Triamcinolon use 64.00% 121 87.6% 106 12.4% 15 0.66§
VA postop (logMAR) 0.4 (0.3; 0.7)
min. 0, max. 1.9
0.4 (0.3; 0.6)
min. 0, max. 1.4
0.9 (0.8; 1.1)
min. 0.5, max. 1.9
< 0.0001#
  1. Overview of the evaluated parameters in the total cohort as well as a comparison between the parameters in the MH closed vs. MH persisting groups. All data except percentages are presented as the median with IQR (median (Q1; Q3)) and range (min., max.). Statistical tests applied: # Mann–Whitney U test; $ Chi-square test; § Fisher’s exact test; Abbreviations: MLD minimum linear diameter, BD base diameter, H max. Height, THI tractional hole index, MHI macular hole index, DHI diameter hole index; Ar area of MH, Cy areas of pseudocysts, VA visual acuity; ns: not significant